Meridian Bioscience announced that it has been awarded $1 million in funding by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative to expedite the launch of the company’s SARS-CoV-2 molecular diagnostic test on the Revogene platform, according to a press release.
Meridian Bioscience has submitted an application for emergency use authorization (EUA) of the assay to the U.S. Food and Drug Administration (FDA).
The assay enables the detection of RNA targets, such as SARS-CoV-2 genomic RNA, directly from viral transport media without pre-dilution in the sample workflow. To achieve this goal, Meridian Bioscience developed a new product formulation to not only optimize the microfluidic properties of its PIE assay device, but to also enable new enzymology and internal processing controls.
